A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway

Pia M. Challita-Eid, Manuel L. Penichet, Seung Uon Shin, Tina Poles, Nima Mosammaparast, Kutubuddin Mahmood, Dennis J. Slamon, Sherie L. Morrison, Joseph D. Rosenblatt

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

We describe the construction and characterization of an Ab fusion protein specific for the tumor-associated Ag HER2/neu linked to sequences encoding the extracellular domain of the B7.1 T cell costimulatory ligand. The Ab domain of the fusion molecule will specifically target HER2/neu- expressing tumor cells, while the B7.1 domain is designed to activate a specific immune response. We show that the B7.1 fusion Ab retained ability to selectively bind to the HER2/neu Ag and to the CTLA4/CD28 counter receptors for B7.1. Specific T cell activation was observed when the B7.1 Ab fusion protein was bound to HER2/neu-expressing cells. The use of the B7.1 Ab fusion protein may overcome limitations of gene transfer and/or standard Ab therapy and represents a novel approach to the eradication of minimal residual disease.

Original languageEnglish
Pages (from-to)3419-3426
Number of pages8
JournalJournal of Immunology
Volume160
Issue number7
StatePublished - Apr 1 1998
Externally publishedYes

Fingerprint Dive into the research topics of 'A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway'. Together they form a unique fingerprint.

  • Cite this

    Challita-Eid, P. M., Penichet, M. L., Shin, S. U., Poles, T., Mosammaparast, N., Mahmood, K., Slamon, D. J., Morrison, S. L., & Rosenblatt, J. D. (1998). A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. Journal of Immunology, 160(7), 3419-3426.